A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Trial Profile

A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 21 Aug 2017 Planned End Date changed from 1 Jan 2019 to 2 Dec 2020.
    • 21 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 2 Dec 2020.
    • 15 Jun 2017 Planned End Date changed from 31 Dec 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top